Equities Analysts Set Expectations for Neogen Q1 Earnings

Key Points

• Analysts at Zacks Research have lowered Neogen's Q1 2026 EPS estimate to $0.05 from a previous estimate of $0.07, with a current full-year earnings consensus of $0.38 per share.
• Institutional investors hold a significant stake in Neogen, with hedge funds owning 96.73% of the company's stock, and various firms recently adjusting their positions.
• Neogen's stock has slipped 0.7% to a price of $5.57, with a one-year low of $3.87 and a high of $17.95, indicating recent volatility in its market performance.

Neogen Corporation (NASDAQ:NEOG - Free Report) - Investment analysts at Zacks Research dropped their Q1 2026 EPS estimates for shares of Neogen in a report released on Tuesday, August 19th. Zacks Research analyst Team now forecasts that the company will post earnings per share of $0.05 for the quarter, down from their previous estimate of $0.07. Zacks Research has a "Hold" rating on the stock. The consensus estimate for Neogen's current full-year earnings is $0.38 per share. Zacks Research also issued estimates for Neogen's Q2 2026 earnings at $0.08 EPS, Q3 2026 earnings at $0.08 EPS, Q4 2026 earnings at $0.08 EPS, Q1 2027 earnings at $0.08 EPS and Q2 2027 earnings at $0.09 EPS.

Other equities research analysts have also recently issued research reports about the stock. William Blair cut shares of Neogen from an "outperform" rating to a "market perform" rating in a research report on Tuesday, July 29th. Guggenheim reduced their target price on shares of Neogen from $13.00 to $10.00 and set a "buy" rating on the stock in a research note on Monday, June 30th. One investment analyst has rated the stock with a Buy rating and three have given a Hold rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Hold" and a consensus target price of $7.50.

Neogen Price Performance

NEOG traded up $0.04 during midday trading on Thursday, hitting $5.64. The company had a trading volume of 2,900,269 shares, compared to its average volume of 6,055,356. The company has a debt-to-equity ratio of 0.42, a quick ratio of 2.22 and a current ratio of 3.32. The company has a market capitalization of $1.23 billion, a PE ratio of -1.12 and a beta of 1.79. Neogen has a twelve month low of $3.87 and a twelve month high of $17.95. The firm's 50-day simple moving average is $5.11 and its 200-day simple moving average is $6.61.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of NEOG. Gates Capital Management Inc. bought a new position in shares of Neogen in the 1st quarter valued at about $79,391,000. Norges Bank acquired a new position in Neogen during the second quarter valued at approximately $43,387,000. Clarkston Capital Partners LLC grew its holdings in Neogen by 123.2% during the second quarter. Clarkston Capital Partners LLC now owns 14,005,725 shares of the company's stock valued at $66,947,000 after purchasing an additional 7,729,650 shares during the period. Millennium Management LLC acquired a new position in Neogen during the first quarter valued at approximately $20,761,000. Finally, Ameriprise Financial Inc. grew its holdings in Neogen by 169.5% during the second quarter. Ameriprise Financial Inc. now owns 3,079,123 shares of the company's stock valued at $14,718,000 after purchasing an additional 1,936,569 shares during the period. Institutional investors own 96.73% of the company's stock.

About Neogen

Neogen Corporation, together with its subsidiaries, engages in the development, manufacture, and marketing of various products and services dedicated to food and animal safety worldwide. It operates through two segments, Food Safety and Animal Safety. The Food Safety segment offers diagnostic test kits and related products to detect dangerous and unintended substances in food and animal feed, including foodborne pathogens, spoilage organisms, natural toxins, food allergens, genetic modifications, ruminant by-products, meat speciation, drug residues, pesticide residues, and general sanitation concerns; and AccuPoint Advanced rapid sanitation test to detect the presence of adenosine triphosphate, a chemical found in living cells, as well as provides genomics-based diagnostic technology and software systems that help testers to objectively analyze and store their results and perform analysis on the results from multiple locations over extended periods.